Stewart W. Strong Sells 733 Shares of Haemonetics Co. (NYSE:HAE) Stock

Haemonetics Co. (NYSE:HAEGet Free Report) insider Stewart W. Strong sold 733 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the transaction, the insider now owns 15,608 shares of the company’s stock, valued at approximately $1,498,992.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Haemonetics Stock Performance

NYSE HAE opened at $95.73 on Friday. The stock has a market capitalization of $4.86 billion, a PE ratio of 41.80, a P/E/G ratio of 1.73 and a beta of 0.34. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The company’s 50 day simple moving average is $86.31 and its two-hundred day simple moving average is $83.30. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50.

Haemonetics (NYSE:HAEGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business had revenue of $343.00 million during the quarter, compared to analysts’ expectations of $329.53 million. During the same quarter in the previous year, the company earned $0.77 EPS. The business’s quarterly revenue was up 12.7% compared to the same quarter last year. Analysts predict that Haemonetics Co. will post 4.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James & Associates grew its stake in shares of Haemonetics by 11.6% during the third quarter. Raymond James & Associates now owns 32,801 shares of the medical instruments supplier’s stock valued at $2,938,000 after buying an additional 3,421 shares during the last quarter. TD Asset Management Inc bought a new stake in shares of Haemonetics in the third quarter worth about $2,114,000. Panagora Asset Management Inc. purchased a new position in Haemonetics during the 3rd quarter valued at about $3,833,000. Teacher Retirement System of Texas lifted its holdings in Haemonetics by 2.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 34,872 shares of the medical instruments supplier’s stock worth $3,124,000 after buying an additional 837 shares during the period. Finally, Knights of Columbus Asset Advisors LLC grew its position in shares of Haemonetics by 1.3% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock worth $896,000 after buying an additional 128 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HAE shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Haemonetics in a report on Friday, May 10th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Barrington Research raised their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. JMP Securities boosted their target price on shares of Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a report on Friday, May 10th. Finally, TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $108.67.

Read Our Latest Research Report on Haemonetics

Haemonetics Company Profile

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Featured Stories

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.